FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078903596> ?p ?o ?g. }

• W2078903596 abstract "Background: mTOR is a significant regulator of cell metabolism, proliferation, autophagy, and is strongly linked to cancer cell survival. This suggests that inhibiting mTOR with everolimus (RAD001) may inhibit tumor cell growth while promoting cell death. The aim was to establish imaging end-points for the efficacy of everolimus in combination with the second generation HSP-90 inhibitor ganetespib in everolimus resistant pancreatic cancer (based on promising results from initial patient trials). This study aimed to establish metabolic (FDG-PET and MRS), morphological (DWI), and anatomical (magnetic resonance imaging, MRI) end-points for mTOR and HSP inhibitor response in mouse pancreatic adenocarcinoma xenografts. Methods: Human Panc-159 tumor xenografts were established in athymic nude mice. Everolimus was administered orally at a daily dose of 5 mg/kg; ganetespib was administered via tail vein injection weekly 100 mg/kg. PET/DWI-MRI imaging was done at baseline, mid-study (Day 8-9), and end of study (Day 21-22). At end of study, mice were sacrificed, and tumors were extracted with perchloric acid for use in 1H-MRS metabolomics. Multivariate analysis was conducted with MetaboAnylast2.0 software. Results: Single treatments showed no significant inhibition of tumor growth or decrease in tumor cellularity. Everolimus single treatment did cause a slight decrease (p = 0.0296 by FDG-PET) in glucose uptake- as previously reported for the mTOR pathway inhibition, while ganetespib alone did not alter glucose uptake. Combination treatment inhibited tumor growth (p= 0.0018 by MRI) in addition to decreasing tumor cellularity (p = 0.0323 by DWI). Combination treatment also decreased tumor metabolic activity as demonstrated through the decrease in glucose uptake (p = 0.0085). Multivariate analysis on combined quantitative metabolic and imaging data sets (including tumor volume, FDG-SUV, cellularity, and 1H-MRS derived concentrations of endogenous metabolites) showed group separation between the control and combination treatment groups. Variables with highest importance in projection (VIP) accounting for group separation were tumor cellularity (VIP = 3.0262), tumor volume (VIP =2.3178), phospholipid-associated glycerol (VIP = 1.9073), and FDG-SUV (VIP = 1.3406). Conclusions: Our study provides the rational of combining everolimus with ganetespib to overcome drug resistance and increase treatment responsiveness in pancreatic cancer. Combination treatment did result in decreased tumor growth, cellularity, phospholipid metabolism and glucose uptake giving potential for these variables to serve as effective biomarkers for therapeutic response once validated in clinical trials. Even though Panc-159 is highly resistant to single everolimus treatment, this combination treatment with an HSP-90 inhibitor provides first evidence of proliferation and metabolic response. Citation Format: Justin Y. Lee, Lora A. Wilson, Jerry Choi, Kendra M. Huber, Andrea L. Merz, Colin D. Weekes, Natalie J. Serkova. A multimodality imaging end-point study of everolimus and ganetespib in treatment of pancreatic cancer: A pre-clinical PET/MRI/MRS study. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4690. doi:10.1158/1538-7445.AM2014-4690" @default.
• W2078903596 created "2016-06-24" @default.
• W2078903596 creator A5018302461 @default.
• W2078903596 creator A5025904775 @default.
• W2078903596 creator A5026482426 @default.
• W2078903596 creator A5045080610 @default.
• W2078903596 creator A5051016940 @default.
• W2078903596 creator A5083575921 @default.
• W2078903596 creator A5091914488 @default.
• W2078903596 date "2014-09-30" @default.
• W2078903596 modified "2023-09-27" @default.
• W2078903596 title "Abstract 4690: A multimodality imaging end-point study of everolimus and ganetespib in treatment of pancreatic cancer: A pre-clinical PET/MRI/MRS study" @default.
• W2078903596 doi "https://doi.org/10.1158/1538-7445.am2014-4690" @default.
• W2078903596 hasPublicationYear "2014" @default.
• W2078903596 type Work @default.
• W2078903596 sameAs 2078903596 @default.
• W2078903596 citedByCount "0" @default.
• W2078903596 crossrefType "proceedings-article" @default.
• W2078903596 hasAuthorship W2078903596A5018302461 @default.
• W2078903596 hasAuthorship W2078903596A5025904775 @default.
• W2078903596 hasAuthorship W2078903596A5026482426 @default.
• W2078903596 hasAuthorship W2078903596A5045080610 @default.
• W2078903596 hasAuthorship W2078903596A5051016940 @default.
• W2078903596 hasAuthorship W2078903596A5083575921 @default.
• W2078903596 hasAuthorship W2078903596A5091914488 @default.
• W2078903596 hasConcept C121608353 @default.
• W2078903596 hasConcept C126322002 @default.
• W2078903596 hasConcept C126838900 @default.
• W2078903596 hasConcept C143409427 @default.
• W2078903596 hasConcept C185592680 @default.
• W2078903596 hasConcept C190283241 @default.
• W2078903596 hasConcept C2775842073 @default.
• W2078903596 hasConcept C2779699572 @default.
• W2078903596 hasConcept C2780210213 @default.
• W2078903596 hasConcept C2989005 @default.
• W2078903596 hasConcept C502942594 @default.
• W2078903596 hasConcept C55493867 @default.
• W2078903596 hasConcept C71924100 @default.
• W2078903596 hasConcept C86554907 @default.
• W2078903596 hasConceptScore W2078903596C121608353 @default.
• W2078903596 hasConceptScore W2078903596C126322002 @default.
• W2078903596 hasConceptScore W2078903596C126838900 @default.
• W2078903596 hasConceptScore W2078903596C143409427 @default.
• W2078903596 hasConceptScore W2078903596C185592680 @default.
• W2078903596 hasConceptScore W2078903596C190283241 @default.
• W2078903596 hasConceptScore W2078903596C2775842073 @default.
• W2078903596 hasConceptScore W2078903596C2779699572 @default.
• W2078903596 hasConceptScore W2078903596C2780210213 @default.
• W2078903596 hasConceptScore W2078903596C2989005 @default.
• W2078903596 hasConceptScore W2078903596C502942594 @default.
• W2078903596 hasConceptScore W2078903596C55493867 @default.
• W2078903596 hasConceptScore W2078903596C71924100 @default.
• W2078903596 hasConceptScore W2078903596C86554907 @default.
• W2078903596 hasLocation W20789035961 @default.
• W2078903596 hasOpenAccess W2078903596 @default.
• W2078903596 hasPrimaryLocation W20789035961 @default.
• W2078903596 hasRelatedWork W130952457 @default.
• W2078903596 hasRelatedWork W1540992897 @default.
• W2078903596 hasRelatedWork W1974483936 @default.
• W2078903596 hasRelatedWork W1984255106 @default.
• W2078903596 hasRelatedWork W2000376927 @default.
• W2078903596 hasRelatedWork W2012846215 @default.
• W2078903596 hasRelatedWork W2023536871 @default.
• W2078903596 hasRelatedWork W2053200494 @default.
• W2078903596 hasRelatedWork W2072574318 @default.
• W2078903596 hasRelatedWork W2081121624 @default.
• W2078903596 hasRelatedWork W2099595692 @default.
• W2078903596 hasRelatedWork W2122564125 @default.
• W2078903596 hasRelatedWork W2145438628 @default.
• W2078903596 hasRelatedWork W2151210831 @default.
• W2078903596 hasRelatedWork W2154684650 @default.
• W2078903596 hasRelatedWork W2165673706 @default.
• W2078903596 hasRelatedWork W2400910579 @default.
• W2078903596 hasRelatedWork W2571925463 @default.
• W2078903596 hasRelatedWork W3091916401 @default.
• W2078903596 hasRelatedWork W2185447366 @default.
• W2078903596 isParatext "false" @default.
• W2078903596 isRetracted "false" @default.
• W2078903596 magId "2078903596" @default.
• W2078903596 workType "article" @default.